Taysha Gene Therapies, Inc. Common Stock

TSHANASDAQ • USD
4.00 USD
↘ 0.10 (2.41%)🟢PRE MARKET (AS OF 04:19 AM EST)
🟢Market: OPEN

Taysha Gene Therapies, Inc. Common Stock (TSHA) is currently trading at $4.00. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, TSHA is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 13, 2026.

Open?$4.22
High?$4.22
Low?$4.00
Prev. Close?$4.10
Volume?6
Avg. Volume?3.8M
VWAP?$4.11
Rel. Volume?0.00x
Bid / Ask
Bid?$3.42 × 100
Ask?$4.99 × 100
Spread?$1.57
Midpoint?$4.21
Valuation & Ratios
Market Cap?1.3B
Shares Out?326.0M
Float?293.5M
Float %?89.2%
P/E Ratio?N/A
P/B Ratio?3.74
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Employees
99
Market Cap
1.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-09-24
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (214) 612-0000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?7.47Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?18.22%High
Short Interest?53.5M
Days to Cover?14.8
Free Float293.5M
Avg Daily Volume3.6M
Settlement Date2026-10-30
Financial Health
Current Ratio?18.56Strong
Quick Ratio?18.56Strong
Cash Ratio?18.42Strong
Debt/Equity?0.13Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
47
3.74FAIR▾
P/S?
Peers
100
S&P
3
243.56HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
175.10HIGH▾
Returns & Efficiency
ROE?
S&P
3
-43.7%WEAK▾
ROA?
S&P
3
-35.9%WEAK▾
Cash Flow & Enterprise
FCF?$-141655000
Enterprise Value?$960.4M
Fundamentals ratios updated end of day